Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Annexin Pharmaceuticals AB: BioStock: Annexin confirms promising results and strengthens financial position

Annexin Pharmaceuticals

Annexin Pharmaceuticals announces that the phase IIa study with its drug candidate ANXV for the eye disease retinal vein occlusion (RVO) has achieved all primary objectives. The results confirm previously reported topline data, demonstrating strong signals of effect and a favourable safety profile. The company has also announced a capital raise of approximately SEK 50 million, primarily for continued investments in the RVO program, a focused clinical study on diabetic retinopathy, but also for studies exploring the potential of ANXV treatment in cancer and sickle cell anemia.

Read the article at biostock.se:

https://www.biostock.se/en/2025/02/annexin-confirms-promising-results-and-strengthens-financial-position/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.